Novel Stem Cell Treatment for Canine Atopic Dermatitis

Purpose:
Our goal is to help dogs suffering from atopic dermatitis (AD) by determining if stem cells can serve as a safe, effective and extended treatment alternative from corticosteroids and/or other medical treatment strategies.

Description:
This pilot clinical study will examine the role of allogenic canine adipose mesenchymal stem cells in treatment of AD in companion dogs. AD is an inflammatory skin disease, characterized by varying degrees of itching, and is associated with environmental allergies. Approximately 10% of dogs suffer from AD and currently all fast-acting symptomatic therapies need frequent administration and can be associated with serious adverse effects. Your pet will be followed closely by our veterinarians to ensure they are happy and comfortable throughout the study. After stem cell administration, we will perform blood tests and monitor the patient for improvements in their itching and other skin lesions.

Client benefits:
- Health screening i.e. blood work, skin scraping, fungal culture and skin cytologies
- Topical flea and tick preventatives (for the duration of the study)
- A $100.00 gift card
- Potential improvement of the pet’s atopic dermatitis condition

Inclusion criteria:
Participants must be…
- Healthy (excluding the presence of atopic dermatitis)
- On effective flea control
- 1+ years of age
- At least 4/9 body condition score
- Under 100lbs

Things to note:
- Enrolled patients will be maintained on a commercial hypoallergenic diet throughout the duration of study
- Participants with a history of medication must observe a withdrawal period for:
  - Cytopoint®, Apoquel® & all glucocorticoids (topical, injectable & oral) – 8 weeks
  - Cyclosporine – 4 weeks
  - Oral antihistamines – 2 weeks
(Topical/oral antimicrobial therapies for secondary infections may be continued, as needed)
During the study, the pet’s diet must remain consistent. Administration of over-the-counter medications will require a consultation with the research team veterinarians.

For further questions regarding this clinical study, please contact:

Western University Pet Health Center
(909) 865-2433

Principal Veterinarian Investigator:
Dr. Gagandeep Kaur DVM PhD

Chad Maki DVM
Chief Medical Officer
VetCell Therapeutics
949-428-0508
cmaki@vetcelltherapeutics.com
www.vetcelltherapeutics.com